* Report out on 4 November * Q3e sales of SEK 225m (+12% y-o-y), EBIT adj.
Gold prices have continued to develop favourably since our previous update in September, up some 20%...
The trade war has both directly and indirectly negatively affected Incap.
Before Taaleri's Q3 2025 results on 28 October, we make slight estimate revisions, reflecting the CM...
Vaisala reports Q3 results on Oct 23. W&E is likely to see its earnings decline in H2 as well, while...
* Q3e: Medical stable, but negative seasonality * EBITA estimates cut by 2-3%, mainly for Engineered...
We trim adjusted EBITA by 2% for 2025E-27E on the back of recent FX movements.
* Report out on 5 November * Q3e sales of SEK 27m (29m), EBIT SEK -5m (-3m) * GC&MP the bright spot,...
Atria raised its 2025 guidance today. The company now expects its adjusted EBIT to to be higher in 2...
Redeye comments on the updated clinical data from the phase I study combining the oncolytic virus TB...
Redeye comments on the phase I data generated from a phase I study combining MesoPher with mitazalim...
Redeye provides a short comment on the recent press release announcing that the CADScor® System has ...
* We cut '25e-'27e adj. EBITA by 4-8% * Expect some EBITA growth in Q3 * NTM EV/EBITA ~9x Expectatio...
Redeye provides a preview of Litium’s Q3 results, set to be released on 23 October.
* Q3e: soft growth but GM improvements * Minor estimate cuts on FX and product mix * Trading at '26e...
Redeye believes gene therapy is an interesting area for imlifidase.
Redeye provides a comment on the Q3 trading update from Cheffelo, released this morning.
Redeye leaves a short comment following OncoZenge’s announcement that UCLA has enrolled the first pa...
Redeye updates its estimates and fair value range following Enviro’s rights issue, where we have als...
* We lift '26e EBIT by 4% on a higher subscription base * 30% '25e-'28e EBIT CAGR driven by Senior s...
